Borneo Journal of Pharmacy <p style="text-align: justify;"><strong>Title:&nbsp;</strong>Borneo Journal of Pharmacy<br><strong>ISSN: </strong><a href="">2621-4814</a> (Online)<br><strong>Subject: </strong>Pharmacy<br> <strong>Frequency: </strong>Quarterly (4 issues per year in February, May, August, and November) onward <strong>February 2020</strong><br><strong>Indexed at: </strong><a href="">EMBASE</a>,&nbsp;<a href="">SINTA 3</a>,<strong>&nbsp;</strong><a href=";search_type=kws&amp;search_field=doi">Dimensions</a>, <a href="">DOAJ</a>,&nbsp;<a href="">Crossref,</a>&nbsp;<a href="">ICI</a>,&nbsp;<a href="">ResearchBib</a>, <a href=";user=R7G787AAAAAJ">Google Scholar,</a> <a href="">Garuda,</a> and more<br> <strong>DOI: </strong><a href="">10.33084/bjop</a><br><strong>Archive preservation: </strong><a href="[]=repoId:IOS6026">Indonesia OneSearch,</a><strong>&nbsp;</strong><a href="">GARUDA Ristekdikti</a><br> <strong>Publisher: </strong><a href="" target="_blank" rel="noopener">Institute for Researches and Community Services</a> <a href="" target="_blank" rel="noopener">Universitas Muhammadiyah Palangkaraya</a><br> <strong>Editor in Chief: </strong><a href="">Mohammad Rizki Fadhil Pratama</a></p> <p style="text-align: justify;"><strong>Borneo Journal of Pharmacy</strong> (<em>Borneo J Pharm</em>, ISSN: <em><a href="">2621-4814</a></em> (online)) is an International Journal managed by&nbsp;<strong><a title="Department of Pharmacy Faculty of Health Science" href="" target="_blank" rel="noopener">Department of Pharmacy Faculty of Health Science</a> <a href="" target="_blank" rel="noopener">Universitas Muhammadiyah Palangkaraya</a></strong>&nbsp;and published four times a year (in February, May, August, and November) onward February 2020 by <strong><a href="" target="_blank" rel="noopener">Institute for Researches and Community Services</a> <a href="" target="_blank" rel="noopener">Universitas Muhammadiyah Palangkaraya</a></strong>, contains articles of research and critical analysis studies in various topics of pharmaceutical science, including&nbsp;<strong>Pharmacology-Toxicology</strong>;&nbsp;<strong>Pharmacognosy-Phytochemistry</strong>;&nbsp;<strong>Pharmaceutical</strong>;&nbsp;<strong>Analytical Pharmacy-Medicinal Chemistry</strong>;&nbsp;<strong>Microbiology Pharmacy</strong>;&nbsp;<strong>Natural Product Development</strong>;&nbsp;<strong>Clinical-Community Pharmacy</strong>;&nbsp;<strong>Management Pharmacy</strong>; and other Pharmacy aspects.</p> <p><a href=""><img src="/public/site/images/adminjournal/SINTA3.png" width="84" height="30"></a></p> <p>Borneo Journal of Pharmacy is accredited at&nbsp;<strong>"<a href="">SINTA 3</a>"</strong>&nbsp;until December 2022 by the Ministry of Research, Technology and Higher Education, Indonesia No: 36/E/KPT/2019.</p> en-US <p style="text-align: justify;">Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.</p> <p style="text-align: justify;">Authors who publish with this journal agree to the following terms:</p> <ol> <li class="show" style="text-align: justify;">Any article on the copyright is retained by the author(s).</li> <li class="show" style="text-align: justify;">The author grants the journal, right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgement of the work authors and initial publications in this journal.</li> <li class="show" style="text-align: justify;">Authors are able to enter into a separate, additional contractual arrangements for the non-exclusive distribution of published articles of work (eg, post-institutional repository) or publish it in a book, with acknowledgement of its initial publication in this journal.</li> <li class="show" style="text-align: justify;">Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process, as can lead to productive exchanges, as well as earlier and greater citation of published work.</li> <li class="show" style="text-align: justify;">The article and any associated published material is distributed under the Creative Commons Attribution-ShareAlike 4.0 International License</li> </ol> (Mohammad Rizki Fadhil Pratama) (Admin LP2M) Mon, 22 Jun 2020 00:00:00 +0000 OJS 60 Cover, Content, and Editorial Note from Borneo J Pharm Vol. 3 Special Issue 1 June 2020 <p style="text-align: justify;">COVID-19 is currently the most researched topic worldwide. Apart from the effects that are caused by such a massive, also because the most effective therapies to treat it has still not been found. Therefore, researchers around the world seem to compete with time to research to find ways to overcome the global pandemic. Seeing this trend, the Borneo Journal of Pharmacy (Borneo J Pharm) does not want to be left behind to participate in sharing information related to COVID-19, and Alhamdulillahirabbil 'alamin, in the middle of 2020 Borneo J Pharm published its first Special Issue with the related Research and Review theme of COVID-19. This edition contains five articles both research articles and reviews from domestic and foreign authors. The authors came from four countries consisting of Indonesia, India, Saudi Arabia, and Nigeria. The authors also come from several institutions, including Kota College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Raffles University, Oxford College of Pharmacy, Shri Gopichand College of Pharmacy, Federal University of Technology Minna, University of Abuja, Benue State Polytechnic, Rahul Sankrityayan College of Pharmacy, Jamia Hamdard, Chhatrapati Shahu Ji Maharaj University, Prince Sattam bin Abdulaziz University, and Universitas Muhammadiyah Bandung</p> ##submission.copyrightStatement## Mon, 22 Jun 2020 00:00:00 +0000 Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review <p style="text-align: justify;">At the end of December 2019, a novel coronavirus was identified which caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a disease known as coronavirus disease 2019 (COVID-19). The virus first originated in the city of Wuhan in China, causing symptoms such as pneumonic plague, which began in the Wuhan and then spread throughout the world with high transmission efficiency. Special precautions and care are needed such as leaving the public area, covering your mouth with a mask, not shaking hands, washing hands, and sanitation from time to time. Infection due to SARS-CoV-2 shows several symptoms, one of which is very often the patient shows difficulty breathing. Currently, COVID-19 has been declared a global pandemic and has almost attacked all countries in the world, including in India which has one of the largest human populations in the entire world. One of the challenges in handling COVID-19 is the unavailability of drugs or special vaccines to treat the disease, so clinical practitioners and academics are currently testing various drugs to see how they affect the COVID-19 patients. Some of the drugs tested provide effective mechanisms against SARS-CoV-2, such as chloroquine, remdesivir, lopinavir, and vaccines under development. These drugs are still being tested and are now at the forefront to combat the effects of SARS-CoV-2 infection. This review article will discuss all kinds of ins and outs of SARS-CoV-2 and COVID-19, including the transmission method, how to prevent it, as well as various drugs and vaccines currently used in handling COVID-19.</p> Mohammad Mukim, Atul Kabra, Siwani Devi, Mohit Chaturvedi, Rakesh Patel ##submission.copyrightStatement## Mon, 22 Jun 2020 00:00:00 +0000 Review on COVID-19: Rise of SARS-CoV-2 Pandemic Outbreak <p style="text-align: justify;">Initially recognized of COVID-19 within the world in 2019, the World Health Organization situational report from May 22<sup>nd</sup>, 2020, globally, there is a complete of 5,204,508 confirmed cases, with 212 countries being affected by the novel coronavirus. 2019 novel coronavirus (SARS-CoV-2) is that the seventh member of the family of coronaviruses is enveloped viruses with a positive sense, single-stranded RNA genome. The SARS-CoV-2 may be a β-CoV of group 2B there is 70% comparability in genetic sequence to SARS-CoV. The source of the new coronavirus infection has been resolved as bats. With whole-genome sequences of SARS-CoV-2 is 96% comparatively at the whole-genome level to a bat coronavirus. Mechanisms of transmission are concluded to incorporate contact, droplet, and possibly airborne under certain circumstances supported ancient experiences associated with SARS-CoV outbreaks. Although antiretroviral therapy is being widely used everywhere the globe for such patents, effects at finding a SARS-CoV vaccine haven’t succeeded so far.</p> Vidhan Chand Bala, Punet Kumar ##submission.copyrightStatement## Mon, 22 Jun 2020 00:00:00 +0000 Preliminary Survey on Knowledge, Attitudes, and Practices about the COVID-19 Pandemic among Residents in North Central Nigeria <p style="text-align: justify;">A preliminary survey on the knowledge, attitude, and practice of the COVID-19 pandemic among residence in North Central Nigeria, was conducted. An anonymous electronic network sampling survey designed by e-survey was employed. The result showed that on the level of knowledge and practice, 76.83% opined that people may be sick for 1-14 days without developing the symptoms. On the viral transmission, 94.41% agreed that the transmission of the virus can be through direct contact with contaminated surfaces through eyes, nose, and mouth, as well as 78.35%, responded that the virus doesn't penetrate the skin. More so 92.04% of the respondents showed that older and sick people are more vulnerable to the disease with 98.86% showing that the most common symptoms may include fever, tiredness, dry cough, and sometimes difficulty in breathing. Only 24.43% asserted that COVID-19 cannot be transmitted through social gatherings, going put often, making direct physical contact with people. Meanwhile, 21.02% showed COVID-19 is a punishment for immoral behavior. On the rate of the outbreak, 94.32% said it is scary. Only 55.11% asserted approval of the control approach by the government. However, 82.29% would agree with the response of the masses to government measures to control the spread. On the way forward, 98.87% advised the need for more research and 87.08% would approve of vaccination against the disease. This implies that the respondents have a good level of knowledge and practice about COVID-19 and necessary adjustments are needed to control or manage the spread of the pandemic.</p> Elijah Edache Ehoche, Johnson Adejoh, Joseph Idoko, Chijioke Madu ##submission.copyrightStatement## Mon, 22 Jun 2020 00:00:00 +0000 Novel Coronavirus: A Newly Arranged Mini-Review <p style="text-align: justify;">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was originally known as a virus that infects animals and rarely can be transmitted to humans in large populations, is now transformed into one of the most feared pandemics causes worldwide. Infection by a virus that is officially known as COVID-19 has caused global concern mainly due to the number of deaths caused. Since it was first reported in Wuhan, China in December 2019, now COVID-19 has spread to almost all parts of the world with a very rapid spread rate. The main symptom of this infection is a respiratory disease accompanied by other symptoms that resemble flu-like illness. Everyone can suffer from COVID-19, but the elderly, toddlers, pregnant women, and people with certain diseases and disorders of the immune system show more severe symptoms. The disease is transmitted through inhalation or contact with droplets, where the incubation period ranges from 2 to 14 days. Until now, specific therapy to treat COVID-19 has not been found, with preventive measures taken to control its spread. In this mini-review, we will explain important information related to COVID-19.</p> Siwani Devi, Kishan Tripathi, Mohammad Mukim, Vidhi Jain, Nesar Ahmad, Noorul Hasan, Prashant Kumar Singh, Mohammad Khalid ##submission.copyrightStatement## Mon, 22 Jun 2020 08:23:02 +0000 Coronavirus-SARS-CoV-2: Biology and Problems in rRT-PCR Detection <p style="text-align: justify;">Coronavirus disease 2019 (COVID-19) first appeared in China in December 2019 and was declared a pandemic by the World Health Organization. COVID-19 is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), a new virus previously unknown to humans. Here we look at what is known about this virus, the main method for detecting the presence of this virus in a person who is used as a golden standard, and the problems that could arise in this detection method. Understanding the biology of the virus and the strengths and weaknesses of the detection method are important for patient management and for overcoming the pandemic.</p> Maelita Ramdani Moeis, Anis Puji Rahayu, Nisa Ihsani, Wulan Pertiwi ##submission.copyrightStatement## Mon, 22 Jun 2020 00:00:00 +0000